LLY
904.44
-0.68%↓
JNJ
233.81
-1.03%↓
ABBV
203.3
-1.4%↓
NVS
146.62
-0.41%↓
AZN
183.22
-0.56%↓
LLY
904.44
-0.68%↓
JNJ
233.81
-1.03%↓
ABBV
203.3
-1.4%↓
NVS
146.62
-0.41%↓
AZN
183.22
-0.56%↓
LLY
904.44
-0.68%↓
JNJ
233.81
-1.03%↓
ABBV
203.3
-1.4%↓
NVS
146.62
-0.41%↓
AZN
183.22
-0.56%↓
LLY
904.44
-0.68%↓
JNJ
233.81
-1.03%↓
ABBV
203.3
-1.4%↓
NVS
146.62
-0.41%↓
AZN
183.22
-0.56%↓
LLY
904.44
-0.68%↓
JNJ
233.81
-1.03%↓
ABBV
203.3
-1.4%↓
NVS
146.62
-0.41%↓
AZN
183.22
-0.56%↓
24h
Atual
Mín
5.54
Máximo
7.43
Rendimento | -69M -102M |
|---|---|
Vendas | -10M 34M |
EPS | -5.69 |
Margem de lucro | -299.886 |
Funcionários | 228 |
EBITDA | 4.7M -18M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +192.79% upside |
Capitalização de Mercado | -267K 157M |
|---|---|
Abertura anterior | 26.57 |
Fecho anterior | 5.68 |
By Acuity
67%
33%
303 / 350 Ranking em Healthcare
By Trading Central
Confiança
Bullish Evidence
5.9501 / 7.66 Suporte e Resistência
O desempenho passado não é um indicador confiável de resultados futuros.
23 de mar. de 2026, 23:47 UTC
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update
DJ
Ler
23 de mar. de 2026, 22:55 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
DJ
Ler
23 de mar. de 2026, 21:51 UTC
Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update
DJ
Ler
23 de mar. de 2026, 23:59 UTC
Global Equities Roundup: Market Talk
DJ
Ler
23 de mar. de 2026, 23:59 UTC
Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk
DJ
Ler
23 de mar. de 2026, 23:50 UTC
Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk
DJ
Ler
23 de mar. de 2026, 23:37 UTC
Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk
DJ
Ler
23 de mar. de 2026, 22:42 UTC
Global Equities Roundup: Market Talk
DJ
Ler
23 de mar. de 2026, 22:42 UTC
Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk
DJ
Ler
23 de mar. de 2026, 22:40 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18B
DJ
Ler
23 de mar. de 2026, 22:23 UTC
Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk
DJ
Ler
23 de mar. de 2026, 22:22 UTC
Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease
DJ
Ler
23 de mar. de 2026, 22:21 UTC
Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales
DJ
Ler
23 de mar. de 2026, 22:21 UTC
Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China
DJ
Ler
23 de mar. de 2026, 22:20 UTC
Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD
DJ
Ler
23 de mar. de 2026, 22:20 UTC
Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD
DJ
Ler
23 de mar. de 2026, 22:19 UTC
Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders
DJ
Ler
23 de mar. de 2026, 22:19 UTC
Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets
DJ
Ler
23 de mar. de 2026, 22:18 UTC
Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD
DJ
Ler
23 de mar. de 2026, 22:15 UTC
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD
DJ
Ler
23 de mar. de 2026, 22:08 UTC
Ebos Needs to Reset Its Gearing Targets -- Market Talk
DJ
Ler
23 de mar. de 2026, 21:42 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
Ler
23 de mar. de 2026, 21:42 UTC
RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk
DJ
Ler
23 de mar. de 2026, 21:32 UTC
WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK
DJ
Ler
23 de mar. de 2026, 21:32 UTC
WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK
DJ
Ler
23 de mar. de 2026, 21:32 UTC
WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK
DJ
Ler
23 de mar. de 2026, 21:10 UTC
Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com
DJ
Ler
23 de mar. de 2026, 20:50 UTC
Tech, Media & Telecom Roundup: Market Talk
DJ
Ler
23 de mar. de 2026, 20:50 UTC
Health Care Roundup: Market Talk
DJ
Ler
23 de mar. de 2026, 20:50 UTC
Basic Materials Roundup: Market Talk
DJ
Ler
Variação de preço
By TipRanks
Previsão para 12 meses
Média 19.5 USD 192.79%
Máximo 28 USD
Mínimo 12 USD
Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Karyopharm Therapeutics Inc - Dist nos últimos 3 meses.
By TipRanks
Compra Forte
5 ratings
5
Comprar
0
Manter
0
Vender
Com base em 5 analistas que deram avaliações de ações para Karyopharm Therapeutics Inc - Dist nos últimos 3 meses.
By Trading Central
Curto Prazo
Bullish Evidence
Recent bullish events outweigh bearish events.
Médio Prazo
Strong Bearish Evidence
All events are bearish.
Longo Prazo
No Evidence
There are no events.
By Acuity
Sentimento de Notícias
Evidência de Tendência de Baixa
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Abaixo da média
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$